



**Q1 2010 reflects the new European partnership agreement with Therabel  
Expected recurrent revenues**

**Paris, April 22, 2010** - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced a consolidated revenue of €6.1 million for the first quarter of 2010 versus €2.6 million in Q1 2009.

Turnover and Cash

The European licensing agreement of Loramyc<sup>®</sup> and Setofilm<sup>®</sup>, signed on March 31st 2010 with Therabel, contributes significantly to the quarterly performance. The upfront payment of €4.5 million paid by this new strategic partner is fully recognized as revenue. Revenues from licenses and other agreements previously signed by BioAlliance with Par Pharmaceutical/Strativa, Handok and NovaMed amount to €1 million, corresponding to the installments of the payments received upon signature.

The turnover of the first quarter of 2010 also includes the direct sales of Loramyc<sup>®</sup> in France for a total amount of €0.6 million, strongly growing compared to the first quarter of 2009 (€0.4 million). The prescriptions of Loramyc<sup>®</sup> are constantly increasing, with nearly 10.000 additional treated patients during the first quarter and more than 60.000 treated patients since launch. At the time BioAlliance is transferring its commercial operations in France to Therabel Hôpital Pharma, the strong image and the significant role of Loramyc<sup>®</sup> in the supportive care area in the hospital setting will be a strong synergistic support for the launch of Setofilm<sup>®</sup> (just approved in 16 European countries). These two products will foster Therabel growth in the European market.

*« With partners in Europe, USA and Asia, BioAlliance now has consistent and experienced structures to organize the commercialization of its first two products, Loramyc<sup>®</sup> and Setofilm<sup>®</sup>, and to generate a recurring revenue stream », said Dominique Costantini, CEO of BioAlliance Pharma. « From now on, Therabel will be in charge of Loramyc<sup>®</sup>'s operations in France and will launch this product, together with Setofilm<sup>®</sup>, in major European countries, once price and reimbursement negotiations are completed. Par/Strativa is expected to launch Loramyc<sup>®</sup> on the US market during the second half of the year, under the brand name Oravig<sup>®</sup> ».*

*« BioAlliance Pharma's cash reserves are significantly reinforced by the partnership agreement with Therabel and the expected upfront payment of \$20 million from Par Pharmaceutical upon approval of Oravig<sup>®</sup> in the United States, obtained on April 16<sup>th</sup> 2010 », adds Nicolas Fellmann, Chief Financial Officer. « As of March 31, thanks to these elements and to the expected reimbursement of the 2009 research tax credit of €1.8 million, the Company has a visibility of nearly two years to finance its projects and its growth, not taking into account potential new license agreements on other portfolio products ».*

### Recent achievements

During the first quarter, significant progress has been achieved for the products of the portfolio:

- With 13 additional approvals, Loramyc® is now registered in 26 European countries,
- The second product, Setofilm®, has been approved in 16 European countries,
- A first clinical phase I trial of fentanyl Lauriad® in chronic cancer pain has confirmed the systemic absorption of fentanyl in healthy volunteers.

In addition, the company is pursuing the clinical development of three promising products in the areas of supportive care and severe and orphan cancers: clonidine Lauriad® in mucositis, doxorubicin Transdrug® nanoparticles in primary liver cancer and AMEP™, a biotherapy in metastatic melanoma. Besides, based on the phase III positive final results for acyclovir Lauriad®, BioAlliance is discussing its registration strategy with the Agencies.

### **About BioAlliance Pharma**

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

BioAlliance Pharma has developed an advanced product portfolio:

Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries

Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries

Acyclovir Lauriad® (Labialis herpes): Positive phase III final results

Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results

AMEP™ (Invasive melanoma): Phase I

Clonidine Lauriad® (Mucositis): Phase II

Doxorubicine Transdrug® (Liver cancer): Phase II

*For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)*

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).*

### **BioAlliance Pharma SA**

Dominique Costantini, CEO

Tel.: +33 1 45 58 76 01

[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

### **ALIZE RP**

Caroline Carmagnol

Tel.: +33 6 64 18 99 59 / [caroline@alizerp.com](mailto:caroline@alizerp.com)